The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
Open accessAbstract
Background Impaired cilial signalling in the melanocortin-4 receptor (MC4R) pathway might contribute to obesity in patients with Bardet-Biedl syndrome and Alström syndrome, rare genetic diseases associated with hyperphagia and early-onset severe obesity. We aimed to evaluate the effect of setmelanotide on bodyweight in these patients.Methods This multicentre, randomised, 14-week double-blind, placebo-controlled, phase 3 trial followed by a 52-week open-label period, was performed at 12 sites (hospitals, clinics, and universities) in the USA, Canada, the UK, France, and Spain. Patients aged 6 years or older were included if they had a clinical diagnosis of Bardet-Biedl syndrome or Alström syndrome and obesity (defined as BMI >97th percentile for age and sex for those aged 6-15 years and ≥30 kg/m 2 for those aged ≥16 years). Patients were randomly assigned (1:1) using a numerical randomisation code to receive up to 3·0 mg of subcutaneous setmelanotide or placebo once per day during the 14-week double-blind period, followed by open-label setmelanotide for 52 weeks. The primary endpoint, measured in the full analysis set, was the proportion of patients aged 12 years or older who reached at least a 10% reduction in bodyweight from baseline after 52 weeks of setmelanotide treatment. This study is registered with ClinicalTrials.gov, NCT03746522.Findings Between Dec 10, 2018, and Nov 25, 2019, 38 patients were enrolled and randomly assigned to receive setmelanotide (n=19) or placebo (n=19; 16 with Bardet-Biedl syndrome and three with Alström syndrome in each group). In terms of the primary endpoint, 32·3% (95% CI 16·7 to 51·4; p=0·0006) of patients aged 12 years or older with Bardet-Biedl syndrome reached at least a 10% reduction in bodyweight after 52 weeks of setmelanotide. The most commonly reported treatment-emergent adverse events were skin hyperpigmentation (23 [61%] of 38) and injection site erythema (18 [48%]). Two patients had four serious adverse events (blindness, anaphylactic reaction, and suicidal ideation); none were considered related to setmelanotide treatment.Interpretation Setmelanotide resulted in significant bodyweight reductions in patients with Bardet-Biedl syndrome; however, these results were inconclusive in patients with Alström syndrome. These results support the use of setmelanotide and provided the necessary evidence for approval of this drug as the first treatment for obesity in patients with Bardet-Biedl syndrome.Funding Rhythm Pharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, setmelanotide can be used in older adults with monogenic obesity, caused by mutations in the leptin signalling pathway, although this is more commonly initiated in children and younger adults with severe and complex obesity [122].”
From Obesity pharmacotherapy in older adults: a narrative review of evidence (2025) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Health-Related Quality of Life of Severely Obese Children and Adolescents
Schwimmer, J. B., Burwinkle, T. M., & Varni, J. W. (2003) · JAMA · doi:10.1001/jama.289.14.1813 · Cited by 1,809
New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey
Beales, P. L., Elcioglu, N. H., Woolf, A. S., Parker, D., & Flinter, F. A. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.6.437 · Cited by 968
Screening for Obesity in Children and Adolescents
US Preventive Services Task Force, Grossman, D. C., Bibbins-Domingo, K. B., Curry, S. J., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.6803 · Cited by 841
Forsythe, E. L., & Beales, P. L. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.115 · Cited by 780
Self-citationClément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W. K., Connors, H., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30364-8 · Cited by 492
Self-citationDavenport, J. R., Watts, A. J., Roper, V. C., Croyle, M. J., van Groen, T., Wyss, J. M., Nagy, T. R., Kesterson, R. A., & Yoder, B. K. (2007) · Current Biology · doi:10.1016/j.cub.2007.08.034 · Cited by 482
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency
Clément, K., Biebermann, H., Farooqi, I. S., der Ploeg, L. H. T. V., Wolters, B., Poitou, C., Puder, L., Fiedorek, F. T., Gottesdiener, K. M., Kleinau, G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0015-9 · Cited by 325
Self-citationMarshall, J. D., Beck, S., Maffei, P., & Naggert, J. Κ. (2007) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201933 · Cited by 242
Clinical Trials in Rare Disease
Augustine, E. F., Adams, H., & Mink, J. W. (2013) · Journal of Child Neurology · doi:10.1177/0883073813495959 · Cited by 223
Cited by
Sorted by citations
Adipose tissue hyperplasia and hypertrophy in common and syndromic obesity-the case of BBS obesity
Horwitz, A., & Birk, R. (2023) · Nutrients · doi:10.3390/nu15153445 · Cited by 143
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Current Treatments for Patients with Genetic Obesity
Faccioli, N., Poitou, C., Clément, K., & Dubern, B. (2023) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2023.2023-3-2 · Cited by 86
Self-citationRoth, C. L., Scimia, C., Shoemaker, A. H., Gottschalk, M., Miller, J., Yuan, G., Malhotra, S., & Abuzzahab, M. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00087-1 · Cited by 76
Self-citationPharmacotherapy for obesity management in adults: 2025 clinical practice guideline update
Pedersen, S. D., Manjoo, P., Dash, S., Jain, A., Pearce, N., & Poddar, M. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.250502 · Cited by 78
Targeting the central melanocortin system for the treatment of metabolic disorders
Sweeney, P., Gimenez, L. E., Hernández, C. C., & Cone, R. D. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00855-y · Cited by 71
Argente, J., Verge, C. F., Okorie, U., Fennoy, I., Kelsey, M. M., Cokkinias, C., Scimia, C., Lee, H.-M., & Farooqi, I. S. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00273-0 · Cited by 55
Self-citationPediatric Obesity: Complications and Current Day Management
Vajravelu, M. E., Tas, E., & Arslanian, S. A. (2023) · Life · doi:10.3390/life13071591 · Cited by 64
Obesity: exploring its connection to brain function through genetic and genomic perspectives
Saeed, S., Bonnefond, A., & Froguel, P. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02737-9 · Cited by 57
Obesity pharmacotherapy in older adults: a narrative review of evidence
Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01529-z · Cited by 51
Forsythe, E. L., Haws, R. M., Argente, J., Beales, P. L., Martos‐Moreno, G. Á., Dollfus, H., Chirila, C., Gnanasakthy, A., Buckley, B. C., Mallya, U. G., et al. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02602-4 · Cited by 42
Self-citationSetmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity
Trapp, C. M., & Censani, M. (2023) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000798 · Cited by 41
Oya, M., Miyasaka, Y., Nakamura, Y., Tanaka, M., Suganami, T., Mashimo, T., & Nakamura, K. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.02.010 · Cited by 46
Syndromic retinitis pigmentosa.
Karuntu, J. S., Almushattat, H., Nguyen, X.-T.-A., Plomp, A. S., Wanders, R. J. A., Hoyng, C. B., van Schooneveld, M. J., Schalij-Delfos, N. E., Brands, M. M., Leroy, B. P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101324 · Cited by 39
Bardet‐Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction
Tomlinson, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15480 · Cited by 42
Shoemaker, A. H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15494 · Cited by 43
Current and future state of pharmacological management of pediatric obesity
Fox, C. K., Kelly, A. S., Reilly, J. L., Theis-Mahon, N. R., & Raatz, S. J. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01465-y · Cited by 38
Barbosa, B. F., de Moraes, F. C. A., Barbosa, C. B., Santos, P. T. K. P., da Silva, I. P., da Silva, B. A. A., Barros, J. C. M., Burbano, R. M. R., dos Santos, N. P. C., & Fernandes, M. R. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13101460 · Cited by 38
Gravina, A. G., Pellegrino, R., Durante, T., Palladino, G., Imperio, G., D’Amico, G., Trotta, M. C., Dallio, M., Romeo, M., D’Amico, M., et al. (2023) · Cells · doi:10.3390/cells12141889 · Cited by 33
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Du, Y., Semghouli, A., Wang, Q., Mei, H., Kiss, L., Baecker, D., Soloshonok, V. A., & Han, J. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400890 · Cited by 29
Fitch, A., Malhotra, S., & Conroy, R. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100110 · Cited by 30
Causes, Consequences, and Preventive Strategies for Childhood Obesity: A Narrative Review
Goel, A., Reddy, S., & Goel, P. (2024) · Cureus · doi:10.7759/cureus.64985 · Cited by 35
Torbahn, G., Lischka, J., Brown, T. J., Ells, L. J., Kelly, A. S., Wabitsch, M., & Weghuber, D. (2024) · Clinical Endocrinology · doi:10.1111/cen.15133 · Cited by 29
Pediatric Obesity Pharmacotherapy: State of the Science, Research Gaps, and Opportunities
Armstrong, S., Eneli, I., Osganian, S. K., Wagner, B. E., Waldrop, S., & Kelly, A. S. (2024) · PEDIATRICS · doi:10.1542/peds.2024-067858 · Cited by 25
Abawi, O., Wahab, R. J., Kleinendorst, L., Blankers, L., Brandsma, A. E., van Rossum, E. F. C., van der Voorn, B., van Haelst, M. M., Gaillard, R., & van den Akker, E. L. T. (2023) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2023.113619 · Cited by 25
An overview of benefits and risks of chronic melanocortin‐1 receptor activation
Böhm, M., Robert, C., Malhotra, S., Clément, K., & Farooqi, I. S. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20269 · Cited by 23
Self-citationEvolving Approaches for Pharmacological Therapy of Obesity
Chao, A. M., Taylor, S. I., Moore, M., Amaro, A., & Wadden, T. A. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031124-101146 · Cited by 29
Ervin, C. M., Norcross, L., Mallya, U. G., Fehnel, S. E., Mittleman, R. S., Webster, M., Haqq, A. M., & Haws, R. M. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02443-y · Cited by 23
Self-citationCrafting Unnatural Peptide Macrocycles via Rh(III)-Catalyzed Carboamidation
Lamartina, C. W., Chartier, C. A., Hirano, J. M., Shah, N. H., & Rovis, T. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c05248 · Cited by 22
Heymsfield, S. B., Clément, K., Dubern, B., Goldstone, A. P., Haqq, A. M., Kühnen, P., Richards, J. R., Roth, C. L., van den Akker, E. L. T., Wabitsch, M., et al. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00601-z · Cited by 23
Self-citationA comprehensive review of genetic causes of obesity
Concepción‐Zavaleta, M. J., Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Osorio, E. R. G., de la Cruz, J. D. C. V., Barrueto-Callirgos, C. M., Puelles‐León, S. L., Alvarado-León, E. D. J., Cabrera, F. A. L., Zavaleta‐Gutiérrez, F. E., et al. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-023-00757-z · Cited by 22
A review of the evidence on cardiovascular outcomes from obesity treatment
Wahab, R. A., & le Roux, C. W. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100071 · Cited by 18
Recent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Cuny, T., Reynaud, R., Raverot, G., Coutant, R., Chanson, P., Kariyawasam, D., Poitou, C., Thomas‐Teinturier, C., Baussart, B., Samara‐Boustani, D., et al. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.07.002 · Cited by 19
Self-citationArnouk, L., Chantereau, H., Courbage, S., Tounian, P., Clément, K., Poitou, C., & Dubern, B. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03085-1 · Cited by 15
Self-citationLazareva, J., Sisley, S. R., Brady, S. M., Smith, A. C. M., Elsea, S. H., Pomeroy, J. J., Roth, C. L., Sprague, J., Wabitsch, M., Garrison, J., et al. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2024.07.001 · Cited by 14
Self-citationLazareva, J., Brady, S. M., & Yanovski, J. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2199152 · Cited by 15
Self-citationSetmelanotide for the Treatment of Acquired Hypothalamic Obesity
Miller, J. L., van Santen, H. M., Phillips, S. A., Hamilton, J., Aberle, J., Sathyapalan, T., Mohamed, Z., McCormack, S. E., Shoemaker, A. H., Kelsey, M. M., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512275 · Cited by 15
Self-citationSyndromic and Monogenic Obesity: New Opportunities Due to Genetic-Based Pharmacological Treatment
Kalinderi, K., Goula, V., Sapountzi, E., Tsinopoulou, V. R., & Fidani, L. (2024) · Children · doi:10.3390/children11020153 · Cited by 15
Qamar, S., Mallik, R., & Makaronidis, J. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.9 · Cited by 16
Ultrasound evaluation of kidney and liver involvement in Bardet–Biedl syndrome
Cetiner, M., Finkelberg, I., Schiepek, F., Pape, L., Hirtz, R., & Büscher, A. K. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03400-w · Cited by 13
Argente, J., Clément, K., Duis, J. B., Farooqi, I. S., Kühnen, P., Miller, J. L., Roth, C. L., & van den Akker, E. L. T. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09984-3 · Cited by 11
Self-citationCuda, S. E., Censani, M., O’Hara, V. M., Paisley, J., Kharofa, R. Y., Conroy, R., Sweeney, B. R., Fernández, C., Gillette, M. L. D., & Browne, N. T. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100113 · Cited by 11
The expanding landscape of genetic causes of obesity
Semenova, E., Guo, A., Liang, H., Hernandez, C. J., John, E. B., & Thaker, V. (2024) · Pediatric Research · doi:10.1038/s41390-024-03780-6 · Cited by 14
Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome
Haqq, A. M., Poitou, C., Chung, W. K., Forsythe, E. L., Conroy, R., Dollfus, H., Malhotra, S., Touchot, N., Okorie, U. C., Beales, P. L., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf079 · Cited by 12
Self-citationFinkelberg, I., Polichronidou, I. M., Hühne, T., Brensing, P., Karaterzi, S., Jaegers, J., Gäckler, A., Pape, L., & Cetiner, M. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03835-9 · Cited by 11
Hühne, T., Polichronidou, I. M., Finkelberg, I., Brensing, P., Jaegers, J., Dinkelbach, L., Kiewert, C., Galetzka, W., Huessler, E., Scherer, T., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf483 · Cited by 11
Management of Monogenic and Syndromic Obesity
Han, J. C., Rasmussen, M. C., Forte, A. R., Schrage, S. B., Zafar, S., & Haqq, A. M. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.005 · Cited by 16
Self-citationUpdate on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing
Ahn, Y. J., Maya, J., & Singhal, V. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00566-z · Cited by 11
Nowak-Ciołek, M., Ciołek, M., Tomaszewska, A., Hildebrandt, F., Kitzler, T. M., Deutsch, K., Lemberg, K., Shril, S., Szczepańska, M., & Zachurzok, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1424819 · Cited by 11
Novel therapeutics in rare genetic obesities: A narrative review
Dubern, B., Faccioli, N., Poitou, C., & Clément, K. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106763 · Cited by 16
Self-citationPrimary cilia and actin regulatory pathways in renal ciliopathies
Kalot, R. K., Sentell, Z. T., Kitzler, T. M., & Torban, E. (2024) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1331847 · Cited by 11
Obesity and Cardiometabolic Disease: Insights From Genetic Studies
Dash, S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.034 · Cited by 10
Ferch, M., Peitsch, I., Kautzky‐Willer, A., Greber‐Platzer, S., Stättermayer, A. F., Krebs, M., & Scherer, T. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf258 · Cited by 8
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
Karam, A., Delvallée, C., Estrada‐Cuzcano, A., Geoffroy, V., Lamouche, J.-B., Leuvrey, A., Nourisson, E., Tarabeux, J., Stoetzel, C., Scheidecker, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108729 · Cited by 10
Self-citationWelling, M. S., de Groot, C. J., Mohseni, M., Meeusen, R. E. H., Boon, M. R., van Haelst, M. M., van den Akker, E. L. T., & van Rossum, E. F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102709 · Cited by 8
Nutrient-Stimulating Hormone-Based Therapies for Obesity
Cristancho, C., Kim, D. W., & Apovian, C. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.006 · Cited by 8
A recent update on childhood obesity: aetiology, treatment and complications
Hawton, K., Shirodkar, D., Siese, T., Hamilton-Shield, J. P., & Giri, D. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0316 · Cited by 11
Collet, T., & Schwitzgebel, V. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1509994 · Cited by 10
Role of hypothalamus function in metabolic diseases and its potential mechanisms
Zhang, X., Yang, J., Li, Y., Li, Y., & Li, G. (2025) · PeerJ · doi:10.7717/peerj.19532 · Cited by 10
Mifsud, F., Chalopin, S., Guillon, E., Faucher, P., Muller, J., Beyec, J. L., Clément, K., & Poitou, C. (2025) · Obesity · doi:10.1002/oby.70002 · Cited by 8
Self-citationClinical and genetic aspects of Bardet–Biedl syndrome in adults in Norway
Rustad, C. F., Bragadóttir, R., Tveten, K., Nordgarden, H., Miller, J. U., Åsten, P. M., Vasconcelos, G., Kulseth, M. A., Holla, Ø. L., Olsen, H. G., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03641-3 · Cited by 7
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. L. T. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf004 · Cited by 6
Genetic Landscape of Obesity in Children: Research Advances and Prospects
Khusainova, R. I., Minniakhmetov, I. R., Vasyukova, O. V., Yalaev, B. I., Ринатович, С. Р., Kopytina, D. A., Guseinova, R. M., Dobreva, E. A., Mel'nichenko, G. A., Dedov, I. I., et al. (2025) · Journal of Obesity · doi:10.1155/jobe/9186826 · Cited by 8
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 12
A diagnostic conundrum in Bardet–Biedl syndrome: when genetic diagnosis precedes clinical diagnosis
Roy, N. V., Heerwegh, S., Dashty, H., Ruys, J., & Coremans, P. (2023) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-23-0055 · Cited by 6
The management of hypothalamic obesity in craniopharyngioma
Dimitri, P. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102018 · Cited by 6
Robinson, G. N., & Pickering, R. J. (2024) · Diabetology · doi:10.3390/diabetology5010006 · Cited by 6
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
CKD in Bardet-Biedl Syndrome: Evidence Supporting Multifactorial Etiology
Zacchia, M., Secondulfo, F., Melluso, A., Blanco, F. D. V., Iorio, V. D., Torella, A., Piluso, G., Capolongo, G., Trepiccione, F., Simonelli, F., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.10.030 · Cited by 5
Polymorphism of Melanocortin Receptor Genes—Association with Inflammatory Traits and Diseases
Bardhan, M., Anand, A., Javed, A., Chilo, M. A., Khan, N., Garg, T., SURANA, A., Huang, H. Y. R., Mondal, M. S., Suresh, V., et al. (2025) · Diseases · doi:10.3390/diseases13090305 · Cited by 5
Multidimensional Characterisation of Eating Behaviour in Genetic Obesity: A Systematic Review
Guillon, E., Dubern, B., Clément, K., & Poitou, C. (2025) · Obesity Facts · doi:10.1159/000548535 · Cited by 6
Self-citationObesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Feng, X., Li, S., Li, J., & Su, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003919 · Cited by 6
Synthetic strategies and therapeutic insights into FDA-approved indole-containing drugs
Yang, T., Zhang, Y., Liu, P., Qi, P., Li, X., Zhi, W., & Zhao, L. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2616556 · Cited by 5
The genetics of obesity: aetiology, prevention and therapy
Bonnefond, A., Bruner, W. S., Grant, S. F. A., Morandi, A., & Froguel, P. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01497-w · Cited by 5
Genetic architecture of obesity and advances in precision pharmacotherapy: a comprehensive review
Kavaja, F., Liehr, T., & Temaj, G. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.15484 · Cited by 6
Clinician’s Guide for Pediatric Anti-obesity Medications
Dutton, W. P., Paddu, N. U., Braddock, A. S., & Sweeney, B. R. (2024) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2024.07.006 · Cited by 5
Obesity and its treatment: Toward new approaches
Segrestin, B., & Cherifi, B. G. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.101712 · Cited by 7
Pomeroy, J. J., Okorie, U. C., Richardson, J. G., Faucher, A., Ionescu‐Ittu, R., Vekeman, F., Huber, C., & Haws, R. M. (2025) · Pediatric Obesity · doi:10.1111/ijpo.70026 · Cited by 5
Self-citationPOMC Neuron BBSome Regulation of Body Weight is Independent of its Ciliary Function
Guo, D., Williams, P. A., Laule, C. F., Seaby, C., Zhang, Q., Sheffield, V. C., & Rahmouni, K. (2023) · Function · doi:10.1093/function/zqad070 · Cited by 5
Cetiner, M., Bergmann, C., Bettendorf, M., Faust, J., Gäckler, A., Gillissen, B., Hansen, M., Kerber, M., Klaus, G., König, J. C., et al. (2024) · Klinische Pädiatrie · doi:10.1055/a-2251-5382 · Cited by 5
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Lawati, A. A., Alhabsi, A. N., Rahul, R., Savino, M.-L., Alwahaibi, H., Das, S., & Lawati, H. A. (2025) · Diseases · doi:10.3390/diseases13050129 · Cited by 5
Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
Dauleh, H., Mohammed, I., & Hussain, K. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf266 · Cited by 4
Setmelanotide-mediated MC4R activation improves hypothalamic obesity via CaMKK2/AMPK pathways
Peng, J., Ou, Y., Zhou, M., Wang, X., Zhang, X., Long, H., Wu, G., Che, M., Li, K., Yang, L., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1730786 · Cited by 4
Current pharmacotherapy options in pediatric obesity
Malíková, J. K., Hainerová, I. A., & Lebl, J. (2023) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2023/017 · Cited by 4
Cardiometabolic Risk Markers in Children With Obesity and Variants in MC4R Pathway-related Genes
Salama, M., Vairo, F. P. E., Hentz, R. C., Nofal, A. A., Hassan, S., Ibrahim, S. H., Lteif, A. N., Creo, A. L., Pittock, S. T., & Kumar, S. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae137 · Cited by 4
Rivera, A., Framnes‐DeBoer, S. N., & Arble, D. M. (2024) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2024.104370 · Cited by 4
Precision medicine to identify, prevent, and treat pediatric obesity
Tillman, E. M., & Mertami, S. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4626 · Cited by 4
Sridharan, K., & Sivaramakrishnan, G. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2465880 · Cited by 4
Obesity Medications and Their Impact on Cardiovascular Health: A Narrative Review
Islam, K. N., Islam, R. K., Tong, V. T., Shami, M. Z., Allen, K. E., Brodtmann, J. R., & Book, J. A. (2024) · Cureus · doi:10.7759/cureus.71875 · Cited by 4
Ashlaw, E. F., Elfers, C., Chichura, K. S., Miranda, I. C., McGivney, A., Chepurny, O. G., Holz, G. G., Mullins, G., den Hartigh, L. J., Liu, Y., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156414 · Cited by 3
The role of primary cilia in physiological and pathological states of the central nervous system
Zhai, D., Zhou, X., Xu, Z., Chen, X., Li, Y., Li, J., Zhou, T., & Xie, S. (2025) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2025.11.011 · Cited by 4
Guo, C., Luo, T., Dong, Y., Lu, J., Xu, Z., Bian, J., Feng, X., Chen, A., Chen, D., & Feng, J. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109370 · Cited by 3
Hitaka, K., Sugawara, T., Matsumoto, M., & Nio, Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02025-2 · Cited by 3
Prindle, C. R., Bennett, T. L., Rajewski, B. H., Kelley, K. J., Impastato, A. C., Potterfield, R., Marks, D. L., & Delev, J. Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1797586 · Cited by 3
A new era in childhood obesity
Martos‐Moreno, G. Á., Guijo, B., Tena‐Sempere, M., Chowen, J. A., & Argente, J. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.03.006 · Cited by 5
Self-citationManagement of Childhood Obesity
Gad, H., Dauleh, H., Mohammed, I., Malik, R. A., & Hussain, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083528 · Cited by 4
Weight Management in a Patient With Smith-Magenis Syndrome: The Role of GLP-1 Receptor Agonists
Correia, J. C., Frayling, T. M., & Pataky, Z. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf094 · Cited by 3
Weight Loss Effect of Lisdexamfetamine in Children with Severe Obesity: A Case Series
Salama, M., Hassan, D., Pittock, S. T., & Kumar, S. (2025) · Childhood Obesity · doi:10.1177/21532176251385703 · Cited by 3
Metadata
- Authors
- Haqq, A. M., Chung, W. K., Dollfus, H., Haws, R. M., Martos-Moreno, G. Á., Poitou, C., Yanovski, J. A., Mittleman, R. S., Yuan, G., Forsythe, E., Clément, K., & Argente, J.
- Affiliations
- University of Alberta (CA)
- Columbia University (US)
- Hôpitaux Universitaires de Strasbourg (FR)
- Marshfield Clinic Research Foundation (US)
- Inserm (FR)
- National Institutes of Health (US)
- Rhythm (United states) (US)
- University College London (GB)
- Corresponding author
- Argente, Jesús
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 10
- Issue
- 12
- Pages
- 859-868
- ISSN
- 2213-8587 (ISSN-L)
- PMC
- PMC9847480
- OpenAlex
- W4308426407
- Cited by
- 206
- References
- 26
- Citations by year
- 2026: 55 · 2025: 62 · 2024: 58 · 2023: 29 · 2022: 1
- FWCI
- 22.61
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-02-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIAHD000641)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- setmelanotide, Bardet-Biedl syndrome, Alström syndrome, melanocortin-4 receptor agonist, early-onset obesity, hyperphagia, weight loss, rare genetic disorders, drug safety, adverse events, children and adolescents, adults, open-label extension, treatment discontinuation
- MeSH terms
- alpha-MSH, Humans, Obesity, Treatment Outcome, Bardet-Biedl Syndrome, Receptor, Melanocortin, Type 4, Alstrom Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
